title: Oestradiol supplement minimises coronary occlusion-induced myocardial infarction and ventricular dysfunction in oophorectomised female rats.
abstract: BACKGROUND
  Endogenous oestrogen deficiency after menopause is associated with high risk of acute cardiac events and the protection of exogenous oestrogen supplements remains uncertain. This study investigates whether oestrogen therapy protects the heart from ischemic injury in oophorectomised rats.
  
  
  METHODS
  Sexually mature female Sprague-Dawley rats (6 for each group) with bilateral oophorectomy underwent selective ligation (occlusion) of left coronary artery for 4 weeks. 17β-oestradiol (E2) supplements (10 μg, i.m., every other day) were started before (preventive-therapeutic supplement) or after coronary occlusion (therapeutic supplement).
  
  
  RESULTS
  In oophorectomised rats plasma levels of E2 declined from 1301 ± 80 to 196 ± 48 pmol/L (p<0.01) and cardiac expression of oestrogen receptors (ER) decreased by ∼60%. E2 supplements recovered the ER expression. Selective ligation of left coronary led myocardial infarction in the left ventricle, with an increase in plasma cardiac troponin I (cTn-I), decrease in systolic blood pressure (SBP), and reduction of left ventricular pressures. Preventive-therapeutic but not therapeutic E2 supplement reduced cTn-I levels (from 21.9 ± 2.0 to 6.0 ± 0.3 ng/mL, p<0.01), minimised infarction (from 37.0 ± 1.2% to 18.1 ± 2.3%, p<0.05), increased SBP (from 82 ± 4.2 to 97 ± 4.4mm Hg, p<0.05), and improved left ventricular end pressures in the oophorectomised rats following coronary occlusion.
  
  
  CONCLUSIONS
  Postmenopausal (ooporectomised) oestrogen supplement commenced before establishment of myocardial ischemia minimises myocardial infarction and ventricular dysfunction following the coronary artery occlusion. Cellular and molecular mechanisms underlying the cardiac protection of oestrogen therapy remain unclear, in which activation of cardiac ER expression and increasing in circulating CD90(+) stem cells may be involved.
authors.affiliation: Department of Cardiology, First Affiliated Hospital, Xi'an Jiao Tong University Medical School, 277 Yanta West Road, Xi'an, Shanxi 710061, PR China.
authors.forename: Xiao-Pu
authors.initials: XP
authors.lastname: Zheng
authors.forename: Ai-Qun
authors.initials: AQ
authors.lastname: Ma
authors.forename: An-Ping
authors.initials: AP
authors.lastname: Dong
authors.forename: Shun
authors.initials: S
authors.lastname: Wang
authors.forename: Wen-Hui
authors.initials: WH
authors.lastname: Jiang
authors.forename: Ting-Zhong
authors.initials: TZ
authors.lastname: Wang
authors.forename: Fen-Ling
authors.initials: FL
authors.lastname: Fan
authors.forename: Shanhong
authors.initials: S
authors.lastname: Ling
mesh_terms: D000818:Animals; D002316:Cardiotonic Agents / Q000008:administration & dosage*; D054059:Coronary Occlusion / Q000097:blood / Q000473:pathology / Q000517:prevention & control*; D019587:Dietary Supplements; D004958:Estradiol / Q000008:administration & dosage*; D005260:Female; D009203:Myocardial Infarction / Q000097:blood / Q000473:pathology / Q000517:prevention & control*; D010052:Ovariectomy; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D018487:Ventricular Dysfunction, Left / Q000097:blood / Q000473:pathology / Q000517:prevention & control*
chemical_list: D002316:Cardiotonic Agents; D004958:Estradiol